IP Library Granted Patent US 8,129,386
Granted Patent B2
US 8,129,386 · App. 12/414,257 · Granted Mar 6, 2012

Fused azole-pyrimidine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,129,386
App. No.
12/414,257
Granted
Mar 6, 2012
Kind
B2
Abstract

The present invention relates to novel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-γ inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoimmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.

Claims (237)

1. A method for treating or controlling asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, an autoimmune pathology, rheumatoid arthritis, Grave's disease, diabetes, cancer, myocardial contractility disorders, or thromboembolism in a human or animal, the method comprising administering to the human or animal an effective amount of a compound of formula (I)

wherein

X represents CR 5 R 6 or NH;

Y 1 represents CR 3 or N;

Chemical bond between Y 2 —Y 3 represents a single bond or double bond, with the proviso that when the Y 2 —Y 3 represents a double bond, Y 2 and Y 3 independently represent CR 4 or N, and

when Y 2 —Y 3 represents a single bond, Y 2 and Y 3 independently represent CR 3 R 4 or NR 4 ;

Z 1 , Z 2 , Z 3 and Z 4 independently represent CH, CR 2 or N;

R l represents

C 1-6 alkyl optionally substituted by mono-, di- or tri- halogen, phenyl, methoxyphenyl, phenoxy, or thienyl,

C 1-6 alkoxy optionally substituted by mono-, di- or tri- halogen, phenyl, methoxyphenyl, phenoxy, or thienyl

or

one of the following carbocyclic and heterocyclic rings selected from the group consisting of cyclopropyl, cyclohexyl, piperidinyl, piperazinyl, pyrrolyl, pyrazolyl, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, isoimidazolyl, pyrazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-triazole, 1,2,4-triazole, 1,2,5-triazole, 1,3,4-triazole, phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1-benzothiophenyl, benzothiazolyl, benzimidazolyl, 3H-imidazo[4,5-b]pyridinyl, benzotriazolyl, indolyl, indazolyl, imidazo[1,2-a]pyridinyl, quinolinyl, and 1,8- naphthyridinyl,

wherein

said carbocyclic and heterocyclic rings optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, N—(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N—(C 1-6 acyl)amino, N—(C 1-6 alkoxycarbonyl)amino, N-(formyl)-N—(C 1-6 alkyl)amino, N[N,N-di(C 1-6 alkyl)amino methylene]amino, N[N,N-di(C 1-6 alkyl)amino (C 1-6 alkylene)methylene]amino, N—[N,N-di(C 1-6 alkyl)amino C 2-6 alkylenyl]amino, C 1-6 alkylthio, C 1-6 alkylanesulfonyl, sulfamoyl, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyridyl, phenyl C 1-6 alkoxycarbonyl,

thiazolyl optionally substituted by pyridyl, piperazinyl optionally substituted by C 1-6 alkyl or C 1-6 alkoxy and

C 1-6 alkyl optionally substituted by mono-, di- or tri- halogen;

R 2 represents hydroxy, halogen, nitro, cyano, carboxy, amino, N—(C 1-6 alkyl)amino, N-(hydroxy C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(hydroxy C 1-6 alkyl)-N- (C 1-6 alkyl)amino, C 2-6 alkenyl, C 1-6 alkoxycarbonyl, aminocaronyl, C 1-6 acyloxy, aminoC 1-6 acyloxy, furyl, morpholino, phenyl, piperidino, aryl,

pyrrolidinyl optionally substituted by C 1-6 acylamino,

piperidino optionally substituted by hydroxy, C 1-6 alkyl, carboxy, aminocarbonyl, N—(C 1-6 alkyl)aminocarbonyl, or N,N-di(C 1-6 alkyl)aminocarbonyl,

piperazinyl optionally substituted by

C 1-6 alkyl,

C 1-6 alkyl optionally substituted by cyano, mono-, di- or tri-halogen, hydroxy, amino, N—(C 1-6 alkyl)amino, N-(hydroxy C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, C 3-6 cycloalkyl, tetrazolyl, tetrahydropyranyl, morpholino, phthalimidyl, 2-oxo-1,3oxazolidinyl, phenyl, —C(O)—R 201 , pypyrrolidinyl optionally substituted by C 1-6 acylamino,

piperidino optionally substituted by hydroxy, C 1-6 alkyl, carboxy, aminocarbonyl, N—(C 1-6 alkyl)aminocarbonyl, or N, N-di(C 1-6 alkyl)aminocarbonyl, or piperazinyl optionally substituted by C 1-6 alkyl,

wherein

R 201 represents hydroxy, amino, N—(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(halobenzyl)amino, C 1-6 alkyl, C 1-6 alkoxy, tetrazolyl, tetrahydropyranyl, morpholino,

pyrrolidinyl optionally substituted by C 1-6 acylamino, piperidino optionally substituted by

hydroxy, C 1-6 alkyl, carboxy, aminocarbonyl, N—(C 1-6 alkyl)aminocarbonyl, or N,N-di(C 1-6 alkyl)aminocarbonyl,

or

piperazinyl optionally substituted by C 1-6 alkyl, C 1-6 alkoxy optionally substituted by cyano, mono-, di- or tri- halogen, hydroxy, C 1-6 alkoxy, hydroxy C 1-6 alkoxy, amino, N—(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, pyrrolyl, tetrazolyl, tetrahydropyranyl, morpholino, phthalimidyl, 2-oxo-1,3oxazolidinyl, phenyl, —C(O)—R 201 ,

pyrrolidinyl optionally substituted by C 1-6 acylamino, piperidino optionally substituted by hydroxy, C 1-6 alkyl, carboxy, aminocarbonyl, N—(C1-6-alkyl)aminocarbonyl, or N,N-di(C 1-6alkyl)aminocarbonyl,

or

piperazinyl optionally substituted by C 1-6 alkyl,

wherein

R 201 represents hydroxy, amino, N—(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(halobenzyl)amino, C 1-6 alkyl, C 1-6 alkoxy, amino C 2-6 alkylenyl, tetrazolyl, tetrahydropyranyl, morpholino, pyrrolidinyl optionally substituted by C 1-6 acylamino, piperidino optionally substituted by hydroxy, C 1-6 alkyl, carboxy, aminocarbonyl, N—(C 1-6 alkyl)aminocarbonyl, or N,N-di(C 1-6 alkyl)aminocarbonyl,

or

piperazinyl optionally substituted by C 1-6 alkyl;

R 3 represents hydrogen, halogen, C 1-6 alkyl optionally substituted by aminocarbonyl, arylC 1-6 alkoxy, or mono-, di- or tri-halogen;

R 4 represents hydrogen or C 1-6 alkyl;

R 5 represents hydrogen or C 1-6 alkyl; and

R 6 represents hydrogen, halogen or C 1-6 alkyl,

a tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof.

2. The method of claim 1 , wherein

X represents CR 5 R 6 or NH;

Y 1 represents N;

Y 2 and Y 3 represent CR 3 R 4 ;

Chemical bond between Y 2 —Y 3 represents a single bond.

Z 4 represents CH;

Z 1 , Z 2 and Z 3 independently represent CH, CR 2 or N;

R 1 represents

C 1-6 alkyl optionally substituted by mono-, di- or tri- halogen, phenyl, methoxyphenyl, phenoxy, or thienyl,

C 1-6 alkoxy optionally substituted by phenyl phenoxy, thienyl or mono-, di- or tri- halogen,

or

one of the following carbocyclic and heterocyclic rings selected from the group consisting of cyclopropyl, cyclopentyl, cyclohexyl, piperidinyl, piperazinyl, pyrrolyl, pyrazolyl, furyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, isoimidazolyl, pyrazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1-benzothiophenyl, benzothiazolyl, benzimidazolyl, 3H-imidazo[4,5-b]pyridinyl, benzotriazolyl, indolyl, indazolyl, imidazo[1,2-a]pyridinyl, quinolinyl, and 1,8-naphthyridinyl,

wherein

said carbocyclic and heterocyclic rings optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, N—(C 1-6 alkyl)amino, N-(hydroxy C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N—(C 1-6 acyl)amino, N—(C 1-6 alkoxycarbonyl)amino, N-(formyl)-N—(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl) amino (C 2-6 alkenyl) amino, N—(C 1-6 alkane)sulfonyl amino, N[N,N-di(C 1-6 alkyl)amino methylene]amino, C 1-6 alkylthio, C 1-6 alkanesulfonyl, sulfamoyl, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, pyrrolyl, imidazolyl, pyrazolyl, pyrrolidinyl, pyridyl, phenyl C 1-6 alkoxycarbonyl, thiazolyl optionally substituted by pyridyl, piperazinyl optionally substituted by C 1-6 alkyl or C 1-6 alkoxy and C 1-6 alkyl optionally substituted by mono-, di- or tri- halogen;

R 2 represents halogen, hydroxy, nitro, cyano, amino, N—(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(hydroxyC 1-6 alkyl)-N—(C 1-6 alkyl)amino, (C 2-6 )alkenyl, C 1-6 alkoxycarbonyl, aminocarbonyl, furyl, piperidino, morpholino, phenyl, pyrrolidinyl optionally substituted by N—(C 1-6 acyl)amino, or N—(C 1-6 alkyl)carbonylamino, piperidino optionally substituted by hydroxy, piperazinyl optionally substituted by C 1-6 alkyl, phenylC 1-6 alkyl, C 1-6 alkoxycarbonyl, or aminocarbonyl;

C 1-6 alkyl optionally substituted by amino, cyano, C 1-6 alkoxycarbonyl, morpholino, or mono-, di- or tri- halogen,

or

C 1-6 alkoxy optionally substituted by hydroxy, cyano, carboxy, C 1-6 alkoxy, C 1-6 acyl, C 1-6 alkoxycarbonyl, amino, N—(C 1-6 alkyl)amino, N—(C 1-6 -alkyl)aminocarbonyl, N,N-di(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)aminocarbonyl, aminocarbonyl, aminoC 1-6 alkylcarbonyl, N-(halo-benzyl)aminocarbonyl, hydroxy C 1-6 alkoxy, C 3-6 cycloalkyl, morpholino, morpholinocarbonyl, pyrrolidinyl, pyrrolyl, piperidino, phthalimidyl,

or

piperazinyl optionally substituted by benzyl;

R 3 represents hydrogen;

R 4 represents hydrogen;

R 5 represents hydrogen; and

R 6 represents hydrogen.

3. The method of claim 1 , wherein

X represents CR 5 R 6 or NH;

Y 1 represents N;

Y 2 and Y 3 represent CR 3 R 4 ;

Chemical bond between Y 2 —Y 3 represents a single bond

Z 4 represents CH;

Z 1 , Z 2 and Z 3 independently represent N, CH or CR 2 ;

R l represents cyclopropyl, cyclopentyl, cyclohexyl, 2-furyl, 3-furyl, imidazolyl, pyrimidinyl, pyridazinyl, piperazinyl, 1,2,3-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, 3 H-imidazo[4,5-b]pyridinyl, 1H-pyrrol-2-yl optionally substituted by C 1-6 alkyl, 1H-pyrrol-3-yl optionally substituted by C 1-6 alkyl, pyrazolyl optionally substituted by 1 or 2 C 1-6 alkyl, isoxazolyl optionally substituted by 1 or 2 C 1-6 alkyl, 2-thienyl optionally substituted by chloro, nitro, cyano, or C 1-6 alkyl, 3-thienyl optionally substituted by chloro, nitro, cyano, or C 1-6 alkyl, piperidinyl optionally substituted by C 1-6 alkoxycarbonyl, or benzyloxycarbonyl, phenyl optionally substituted by 1 to 3 substituents selected from the group consisting of fluoro, chloro, hydroxy, nitro, cyano, carboxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, amino, N—(C 1-6 alkyl)amino, N—(C 1-6 acyl)amino, N—(C 1-6 alkoxycarbonyl)amino, N,N-di(C 1-6 alkyl)amino, N-(formyl)-N—C 1-6 alkyl amino, C 1-6 alkylthio, C 1-6 alkanesulfonyl, sulfamoyl, pyrrolyl, imidazolyl, pyrazolyl, and piperazinyl optionally substituted by C 1-6 alkyl,

pyridyl optionally substituted by 1 or 2 substituents selected from the group consisting of chloro, hydroxy, carboxy, C 1-6 alkoxy, C 1-6 alkylthio, amino, N—(C 1-6 alkyl)amino, N-(hydroxyC 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N—(C 1-6 acyl)amino, N—(C 1-6 alkane)sulfonyl amino, N[N,N-di(C 1-6 alkyl)amino methylene]amino, and C 1-6 alkyl optionally substituted by tri halogen,

pyrazinyl optionally substituted by C 1-6 alkyl, 1,3-thiazolyl optionally substituted by 1 or 2 substituents selected from the group consisting of C 1-6 alkyl, pyridyl and N—(C 1-6 alkoxycrbonyl)amino,

indolyl optionally substituted by C 1-6 alkyl,

benzimidazolyl optionally substituted by C 1-6 alkyl or tri-halo C 1-6 alkyl,

1,2,3-benzotriazolyl optionally substituted by C 1-6 alkyl,

1,8-naphthyridinyl optionally substituted by C 1-6 alkyl optionally substituted by tri halogen,

C 1-6 alkyl optionally substituted by tri- halogen, phenyl, phenoxy, or thienyl,

or

C 1-6 alkoxy optionally substituted by phenyl, phenoxy, or thienyl;

R 2 represents fluoro, chloro, bromo, hydroxy, nitro, vinyl, cyano, amino, aminoacetoxy, N—(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(hydroxyC 1-6 alkyl)-N—(C 1-6 alkyl)amino, 2-furyl, piperidino, morpholino, phenyl, pyrrolidinyl optionally substituted by acetamido,

piperidino optionally substituted by hydroxy, piperazinyl optionally substituted by methyl, benzyl, C 1-6 alkoxycarbonyl, or aminocarbonyl,

C 1-6 alkyl optionally substituted by cyano, tri-fluoro, carboxy, methoxycarbonyl, aminocarbonyl, tert-butoxycarbonyl, tetrahydropyranyl, or morpholino, C 1-6 alkoxy optionally substituted by hydroxy, cyano, methoxy, methoxycarbonyl, tert-butoxycarbonyl, carboxy, aminoacetyl, dimethylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, isopropylaminocarbonyl, fluorobenzylaminocarbonyl, cyclopropyl, pyrrolidinyl, piperidino , tetrahydropyranyl, morpholino, morpholinocarbonyl, 2-oxo-1,3-oxazolidin-4-yl, phthalimid-N-yl, or hydroxy C 1-6 alkyleneoxy,

R 3 represents hydrogen;

R 4 represents hydrogen;

R 5 represents hydrogen; and

R 6 represents hydrogen.

4. The method of claim 1 , wherein

X represents CR 5 R 6 or NH;

Y l represents N;

Y 2 and Y 3 represent CR 3 R 4 ;

Chemical bond between Y 2 —Y 3 represents a single bond

Z 3 and Z 4 represent CH;

Z 1 and Z 2 independently represent CH or CR 2 ;

R 1 represents cyclopropyl, cyclopentyl, cyclohexyl, 2-furyl, 3-furyl, imidazolyl, 1H-pyrrol-2-yl, 1H-pyrrol-3-yl, pyrimidinyl, pyridazinyl, piperazinyl, 1,2,3-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, 3H-imidazo[4,5-b]pyridinyl,

pyrrolyl optionally substituted by C 1-6 alkyl, pyrazolyl optionally substituted by 1 or 2 C 1-6 alkyl, isoxazolyl optionally substituted by 1 or 2 C 1-6 alkyl, 2-thienyl optionally substituted by chloro, nitro, cyano, or C 1-6 alkyl, 3-thienyl optionally substituted by chloro, nitro, cyano, or C 1-6 alkyl,

piperidinyl optionally substituted by C 1-6 alkoxycarbonyl, or benzyloxycarbonyl,

phenyl optionally substituted by 1 to 3 substituents selected from the group consisting of fluoro, chloro, hydroxy, nitro, cyano, carboxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, amino, N—(C 1-6 alkyl)amino, N—(C 1-6 acyl)amino, N—(C 1-6 alkoxycabonyl)amino, N,N-di(C 1-6 alkyl)amino, N-(formyl)-N—C 1-6 alkyl amino, C 1-6 alkylthio, C 1-6 alkanesulfonyl, sulfamoyl, pyrrolyl, imidazolyl, pyrazolyl, and piperazinyl optionally substituted by C 1-6 alkyl,

pyridyl optionally substituted by 1 or 2 substituents selected from the group consisting of chloro, hydroxy, carboxy, C 1-6 alkoxy, C 1-6 alkylthio, amino, N—(C 1-6 alkyl)amino, N-(hydroxyC 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N—(C 1-6 acyl)amino, N—(C 1-6 alkane)sulfonyl amino, N[N,N-di(C 1-6 alkyl)amino methylene]amino, and C 1-6 alkyl optionally substituted by tri halogen,

pyrazinyl optionally substituted by C 1-6 alkyl, 1,3-thiazolyl optionally substituted by

1 or 2 substituents selected from the group consisting of C 1-6 alkyl, pyridyl and N—(C 1-6 alkoxycrbonyl)amino, indolyl optionally substituted by C 1-6 alkyl, benzimidazolyl optionally substituted by C 1-6 alkyl or tri-halo C 1-6 alkyl, 1,2,3-benzotriazolyl optionally substituted by C 1-6 alkyl, 1,8-naphthyridinyl optionally substituted by C 1-6 alkyl optionally substituted by tri halogen,

C 1-6 alkyl optionally substituted by tri- halogen, phenyl, phenoxy, or thienyl,

or

C 1-6 alkoxy substituted by phenyl, phenoxy, or thienyl;

R 2 represents fluoro, chloro, bromo, hydroxy, nitro, vinyl, cyano, amino, amino-acetoxy, N-(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(hydroxyC 1-6 alkyl)-N—(C 1-6 alkyl)amino, 2-furyl, piperidino, morpholino, phenyl,

pyrrolidinyl optionally substituted by acetamido,

piperidino optionally substituted by hydroxy,

piperazinyl optionally substituted by methyl, benzyl, C 1-6 alkoxycarbonyl, or aminocarbonyl,

C 1-6 alkyl optionally substituted by cyano tri-fluoro, carboxy, methoxycarbonyl, aminocarbonyl, tert-butoxycarbonyl, tetrahydropyranyl, or morpholino,

or

C 1-6 alkoxy optionally substituted by hydroxy, cyano, methoxy, methoxycarbonyl, tert-butoxycarbonyl, carboxy, aminoacetyl, dimethylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, isopropylaminocarbonyl, fluorobenzylaminocarbonyl, cyclopropyl, pyrrolidinyl, piperidino, tetrahydropyranyl, morpholino, morpholinocarbonyl, 2-oxo-1,3-oxazolidin-4-yl, phthalimid-N-yl, or hydroxy C 1-6 alkyleneoxy;

R 3 represents hydrogen;

R 4 represents hydrogen;

R 5 represents hydrogen; and

R 6 represents hydrogen.

5. The method of claim 1 , wherein

X represents CR 5 R 6 or NH;

Y 1 represents N;

Y 2 and Y 3 represent CR 3 R 4 ;

Chemical bond between Y 2 —Y 3 represents a single bond

Z 1 and Z 4 represent CH;

Z 2 and Z 3 independently represent CH or CR 2 ;

R l represents cyclopropyl, cyclopentyl, cyclohexyl, 2-furyl, 3-furyl, imidazolyl, 1H-pyrrol-2-yl, 1H-pyrrol-3-yl, pyrimidinyl, piperazinyl, pyridazinyl, 1,2,3-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, 3H-imidazo[4,5-b]pyridinyl,

pyrrolyl optionally substituted by C 1-6 alkyl,

pyrazolyl optionally substituted by 1 or 2 C 1-6 alkyl,

isoxazolyl optionally substituted by 1 or 2 C 1-6 alkyl,

2-thienyl optionally substituted by chloro, nitro, cyano, or C 1-6 alkyl,

3-thienyl optionally substituted by chloro, nitro, cyano, or C 1-6 alkyl,

piperidinyl optionally substituted by C 1-6 alkoxycarbonyl, or benzyloxycarbonyl,

phenyl optionally substituted by 1 to 3 substituents selected from the group consisting of fluoro, chloro, hydroxy, nitro, cyano, carboxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkoxycarbonyl, amino, N—(C 1-6 alkyl)amino, N—(C 1-6 acyl)amino, N—(C 1-6 alkoxycabonyl)amino, N,N-di(C 1-6 alkyl)amino, N-(formyl)-N—C 1-6 alkyl amino, C 1-6 alkylthio, C 1-6 alkanesulfonyl, sulfamoyl, pyrrolyl, imidazolyl, pyrazolyl, and piperazinyl optionally substituted by C 1-6 alkyl,

pyridyl optionally substituted by 1 or 2 substituents selected from the group consisting of chloro, hydroxy, carboxy, C 1-6 alkoxy, C 1-6 alkylthio, amino, N—(C 1-6 alkyl)amino, N-(hydroxyC 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N—(C 1-6 acyl)amino, N—(C 1-6 alkane)sulfonyl amino, N[N,N-di(C 1-6 alkyl)amino methylene]amino, C 1-6 alkoxyphenylC 1-6 alkoxy, and C 1-6 alkyl optionally substituted by tri halogen,

pyrazinyl optionally substituted by C 1-6 alkyl,

1,3-thiazolyl optionally substituted by 1 or 2 substituents selected from the group consisting of C 1-6 alkyl, pyridyl and N—(C 1-6 alkoxycrbonyl)amino, indolyl optionally substituted by C 1-6 alkyl,

benzimidazolyl optionally substituted by C 1-6 alkyl or tri-halo C 1-6 alkyl,

1,2,3-benzotriazolyl optionally substituted by C 1-6 alkyl, 1,8-naphthyridinyl optionally substituted by C 1-6 alkyl optionally substituted by tri halogen,

C 1-6 alkyl optionally substituted by tri- halogen, phenyl, phenoxy, or thienyl,

or

C 1-6 alkoxy substituted by phenyl, phenoxy, or thienyl;

R 2 represents fluoro, chloro, bromo, hydroxy, nitro, vinyl, cyano, amino, aminoacetoxy, N—(C 1-6 alkyl)amino, N,N-di(C 1-6 alkyl)amino, N-(hydroxyC 1-6 alkyl)-N—(C 1-6 alkyl)amino, 2-furyl, piperidino, morpholino, phenyl,

pyrrolidinyl optionally substituted by acetamido, piperidino optionally substituted by hydroxy, piperazinyl optionally substituted by methyl, benzyl, C 1-6 alkoxycarbonyl, or aminocarbonyl,

C 1-6 alkyl optionally substituted by cyano, tri-fluoro, carboxy, methoxycarbonyl,

aminocarbonyl, tert-butoxycarbonyl, tetrahydropyranyl, or morpholino,

or

C 1-6 alkoxy optionally substituted by hydroxy, cyano, methoxy, methoxycarbonyl, tert-butoxycarbonyl, carboxy, aminoacetyl, dimethylamino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, isopropylaminocarbonyl, fluorobenzylaminocarbonyl, cyclopropyl, pyrrolidinyl, piperidino, tetrahydropyranyl, morpholino, morpholinocarbonyl, tetrazolyl, 2-oxo-1,3-oxazolidin-4y1, phthalimid-N-yl, or hydroxy C 1-6 alkyleneoxy;

R 3 represents hydrogen;

R 4 represents hydrogen;

R 5 represents hydrogen; and

R 6 represents hydrogen.

6. The method of claim 1 , wherein

X represents CR 5 R 6 or NH;

Y 1 represents N;

Y 2 and Y 3 represent CR 3 R 4 ;

Chemical bond between Y 2 —Y 3 represents a single bond

Z 3 and Z 4 represent CH;

Z 1 and Z 2 independently represent CH or CR 2 ;

R l represents 3H-imidazo[4,5-b]pyridinyl, benzimidazolyl

pyridyl optionally substituted by hydroxy, amino, acetamido, methoxybenzyloxy or methylsulfonylamino,

or

1,3-thiazolyl optionally substituted by 1 or 2 methyl;

R 2 represents fluoro, chloro, bromo, morpholino, piperazinyl, methylpiperazinyl, methyl, tri-fluoro methyl, or C 1-6 alkoxy optionally substituted by hydroxy, cyano, carboxy, dimethylaminocarbonyl, tetrahydropyranyl, morpholino, morpholinocarbonyl, tetrazolyl, or phthalimid-N-yl;

R 3 represents hydrogen;

R 4 represents hydrogen;

R 5 represents hydrogen; and

R 6 represents hydrogen.

7. The method of claim 1 , wherein

X represents CR 5 R 6 or NH;

Y l represents N;

Y 2 and Y 3 represent CR 3 R 4 ;

Chemical bond between Y 2 —Y 3 represents a single bond;

Z 1 , Z 3 and Z 4 represent CH;

Z 2 represents CR 2 ;

R l represents 3H-imidazo[4,5-b]pyridinyl, benzimidazolyl pyridyl optionally substituted by hydroxy, amino, acetamido, methoxybenzyloxy or methylsulfonylamino,

or

1,3-thiazolyl optionally substituted by 1 or 2 methyl,

R 2 represents fluoro, chloro, bromo, morpholino, piperazinyl, methylpiperazinyl, methyl, tri-fluoro methyl, C 1-6 alkoxy optionally substituted by hydroxy, cyano, carboxy, dimethylaminocarbonyl, tetrahydropyranyl, morpholino, morpholinocarbonyl, tetrazolyl, or phthalimid-N-yl;

R 3 represents hydrogen;

R 4 represents hydrogen;

R 5 represents hydrogen; and

R 6 represents hydrogen.

8. The method of claim 1 , wherein said compound is selected from the group consisting of:

N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide;

2-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1-pyridin-3-ylethylenol;

N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1H-benzimidazole-5-carboxamide;

6-(acetamido)-N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide;

N-{5-[2-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1-hydroxyvinyl]pyridin-2-yl}acetamide;

2-({5-[2-hydroxy-2-pyridin-3-ylvinyl]-7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-8-yl}oxy)-N,N-dimethylacetamide;

2-[7-methoxy-8-(tetrahydro-2H-pyran-2-ylmethoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-1-pyridin-3-ylethylenol;

2-[8-(2-hydroxyethoxy)-7-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl]-1-pyridin-3-ylethylenol;

({5-[2-hydroxy-2-pyridin-3-ylvinyl]-7-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-8-yl}oxy)acetic acid;

4-({5-[2-hydroxy-2-pyridin-3-ylvinyl]-7-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-8-yl}oxy)butanoic acid;

({5-[2-hydroxy-2-pyridin-3-ylvinyl]-7-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-8-yl}oxy)acetonitrile;

2-[7-methoxy-8-(2H-tetrazol-5-ylmethoxy)-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl]-1-pyridin-3-ylethylenol;

2-[7-methoxy-8-(4-morpholin-4-yl-4-oxobutoxy)-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl]-1-pyridin-3-ylethylenol;

5-[1-hydroxy-2-(8-morpholin-4-yl-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)vinyl]pyridin-3-ol ;

N-(2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)-5-hydroxynicotinamide;

6-(acetamido)-N-(7,9-dimethoxy-8-methyl-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)nicotinamide;

N-(8 ,9-dimethoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)-5-hydroxynicotinamide;

5-hydroxy-N-(7-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)nicotinamide;

N-(7, 8-dimethoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)-5-[(4-methoxybenzyl)oxy]nicotinamide;

N-(7, 8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-5-hydroxynicotinamide;

5-hydroxy-N-[8-(trifluoromethyl)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]nicotinamide;

N-{8-[3-(1 ,3-dioxo-1 ,3-dihydro-2H-isoindo1-2-yl)propoxy]-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl}nicotinamide;

N-(7-bromo-8-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)nicotinamide;

6-amino-N-(8-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)nicotinamide;

1-(1H-benzimidazol-5-yl)-2-(8,9-dimethoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)ethylenol;

2-(8,9-dimethoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)-1-(2,4-dimethyl-1 ,3-thiazol-5-yl)ethylenol;

N-(9-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1H-benzimidazole-5-carboxamide;

N-(8-bromo-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)nicotinamide;

N-(8-bromo-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)-1H-benzimidazole-5-carboxamide;

N-(8-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)-1H-benzimidazole-5-carboxamide;

N-(8-methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1H-benzimidazole-5-carboxamide;

N-[8-(trifluoromethyl)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-1H-benzimidazole-5-carboxamide;

N-(7-fluoro-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1H-benzimidazole-5-carboxamide;

N-(7-methoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)nicotinamide;

N-(8-chloro-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)-1H-benzimidazole-5-carboxamide;

6-(acetamido)-N-(8-morpholin-4-yl-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)nicotinamide;

1-(1H-benzimidazol-5-yl)-2-(8-morpholin-4-yl-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)ethylenol;

N-{5-[1-hydroxy-2-(8-morpholin-4-yl-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)vinyl]pyridin-2-yl}acetamide;

6-methyl-N-(8-morpholin-4-yl-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)nicotinamide;

1-(1H-benzimidazol-5-yl)-2[8-(4-methylpiperazin-1-yl)-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl]ethylenol;

N-(2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-3H-imidazo[4,5-b]pyridine-6-carboxamide;

N-(7,8-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-3H-imidazo[4,5-b]pyridine-6-carboxamide;

N-[7-(trifluoromethyl)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]-1H-benzimidazole-5-carboxamide;

N-(7,9-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1H-benzimidazole-5-carboxamide;

N-{5[2-(7,9-dimethoxy-8-methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1-hydroxyvinyl]pyridin-2-yl}acetamide;

N-{5[2-(7-bromo-9-methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1-hydroxyvinyl]pyridin-2-yl}acetamide; and

2-(8,9-dimethoxy-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl)-1-pyridin-3-ylethylenol.

9. The method of claim 1 , wherein the compound is administered for treating or controlling asthma, rhinitis, allergic diseases, or an autoimmune pathology.

10. The method of claim 4 , wherein the compound is administered for treating or controlling asthma, rhinitis, allergic diseases, or an autoimmune pathology.

11. The method of claim 6 , wherein the compound is administered for treating or controlling asthma, rhinitis, allergic diseases, or an autoimmune pathology.

12. The method of claim 8 , wherein the compound is administered for treating or controlling asthma, rhinitis, allergic diseases, or an autoimmune pathology.

13. The method of claim 1 , wherein the compound is administered for treating or controlling diabetes, cancer, or myocardial contractility disorders.

14. The method of claim 4 , wherein the compound is administered for treating or controlling diabetes, cancer, or myocardial contractility disorders.

15. The method of claim 6 , wherein the compound is administered for treating or controlling diabetes, cancer, or myocardial contractility disorders.

16. The method of claim 8 , wherein the compound is administered for treating or controlling diabetes, cancer, or myocardial contractility disorders.

Assignments (9)
CHANGE OF ADDRESS Recorded Jun 12, 2023
From: BAYER INTELLECTUAL PROPERTY GMBH
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 064021/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2017
From: BAYER AKTIENGESELLSCHAFT
To: BAYER HEALTHCARE AG
Reel/Frame 043711/0996 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2017
From: BAYER HEALTHCARE AG
To: BAYER PHARMACEUTICALS CORPORATION
Reel/Frame 043712/0221 →
NUNC PRO TUNC ASSIGNMENT Recorded Sep 27, 2017
From: BAYER PHARMACEUTICALS CORPORATION
To: BAYER HEALTHCARE AG
Reel/Frame 043712/0536 →
MERGER Recorded Sep 27, 2017
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 044048/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2017
From: SHIMADA, MITSUYUKI; MURATA, TOSHIKI; FUCHIKAMI, KINJI; TSUJISHITA, HIDEKI; OMORI, NAOKI; KATO, ISSEI; MIURA, MAMI; URBAHNS, KLAUS; GANTNER, FLORIAN; BACON, KEVIN
To: BAYER AKTIENGESELLSCHAFT
Reel/Frame 043703/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030516/0512 →
CHANGE OF NAME Recorded Apr 11, 2013
From: BAYER SCHERING PHARMA AG
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030199/0001 →
CHANGE OF NAME Recorded Nov 11, 2012
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 029277/0286 →